Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DGX | Common Stock | Options Exercise | $56.8K | +1.01K | +4.22% | $56.25 | 24.9K | Jul 1, 2022 | Direct | F1 |
transaction | DGX | Common Stock | Options Exercise | $58.1K | +990 | +3.97% | $58.69 | 25.9K | Jul 1, 2022 | Direct | F1 |
transaction | DGX | Common Stock | Sale | -$267K | -2K | -7.71% | $133.47 | 23.9K | Jul 1, 2022 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DGX | Stock Options (Right to Buy) | Options Exercise | -$56.8K | -1.01K | -87.14% | $56.25 | 149 | Jul 1, 2022 | Common Stock | 1.01K | $56.25 | Direct | F1 |
transaction | DGX | Stock Options (Right to Buy) | Options Exercise | -$58.1K | -990 | -100% | $58.69 | 0 | Jul 1, 2022 | Common Stock | 990 | $58.69 | Direct | F1 |
transaction | DGX | Phantom Stock Units | Award | $41.5K | +308 | +2.56% | $134.74 | 12.4K | Jul 1, 2022 | Common Stock | 308 | $0.00 | Direct | F2, F3 |
Id | Content |
---|---|
F1 | This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 1, 2022. |
F2 | Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. |
F3 | Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. |